Charles River has been riding rough waters in 2024, and as the CRO’s CEO predicted, the third quarter proved no exception. | ...

The Wilmington-based contract research organization offered new details in its third-quarter earnings about its ongoing ...

Charles River Trader, part of the Charles River Investment Management System, offers full order and execution management (OEMS) in a single system. Charles River Trader supports multi-currency trading ...

Charles River Laboratories raised its full-year profit forecast after beating analysts' estimates for quarterly results as the contract research firm expects demand to stabilize from biotech clients ...

In a report released on November 7, Patrick B Donnelly from Citi maintained a Sell rating on Charles River Labs (CRL – Research Report).

A charter company working for Charles River Laboratories, one of the largest U.S. clinical research organizations, was recently fined by Canadian authorities for improperly shipping long-tailed ...

Charles River Laboratories International Inc (NYSE:CRL) reported third-quarter 2024 revenue of $1.01 billion on Wednesday, a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Investors with significant funds have taken a bullish position in Charles River CRL, a development that retail traders should be aware of. This was brought to our attention today through our ...

Barrington raised the firm’s price target on Charles River Associates (CRAI) to $212 from $194 and keeps an Outperform rating on the ...

Charles River Laboratories International Inc. (CRL) on Wednesday reported third-quarter earnings of $69.7 million. On a per-share ...

Charles River Labs provides products and services to pharma and biotech companies to help accelerate research and drug ...